OrthoPediatrics Corp. (NASDAQ:KIDS) Receives $24.67 Consensus PT from Brokerages

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $24.6667.

Several research firms have recently commented on KIDS. Truist Financial lifted their price target on shares of OrthoPediatrics from $19.00 to $20.00 and gave the company a “hold” rating in a report on Monday, March 2nd. Wall Street Zen upgraded shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. TD Cowen raised shares of OrthoPediatrics to a “strong-buy” rating in a report on Tuesday, January 27th. BTIG Research lifted their target price on OrthoPediatrics from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a report on Thursday, January 22nd.

OrthoPediatrics Stock Performance

KIDS stock opened at $15.87 on Friday. The stock’s 50 day simple moving average is $17.20 and its 200 day simple moving average is $17.63. OrthoPediatrics has a 12-month low of $14.91 and a 12-month high of $26.40. The firm has a market cap of $401.19 million, a P/E ratio of -9.39 and a beta of 1.07. The company has a current ratio of 5.55, a quick ratio of 2.65 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. The firm had revenue of $61.61 million during the quarter, compared to the consensus estimate of $61.27 million. OrthoPediatrics had a negative net margin of 16.77% and a negative return on equity of 6.70%. As a group, equities research analysts predict that OrthoPediatrics will post -0.93 EPS for the current year.

Insider Buying and Selling at OrthoPediatrics

In related news, insider Gregory A. Odle sold 8,433 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $17.25, for a total transaction of $145,469.25. Following the completion of the transaction, the insider directly owned 187,735 shares in the company, valued at $3,238,428.75. This represents a 4.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David R. Bailey sold 19,535 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $17.25, for a total value of $336,978.75. Following the completion of the sale, the chief executive officer directly owned 298,020 shares in the company, valued at $5,140,845. This represents a 6.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 58,171 shares of company stock worth $1,003,450. 31.80% of the stock is owned by company insiders.

Institutional Trading of OrthoPediatrics

A number of large investors have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its position in OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after purchasing an additional 1,139 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after purchasing an additional 2,561 shares during the last quarter. Caption Management LLC acquired a new stake in shares of OrthoPediatrics in the third quarter valued at approximately $54,000. BNP Paribas Financial Markets increased its stake in shares of OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,235 shares during the period. Finally, State of Wyoming raised its holdings in shares of OrthoPediatrics by 189.7% during the fourth quarter. State of Wyoming now owns 6,822 shares of the company’s stock valued at $121,000 after buying an additional 4,467 shares during the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.